EYEN vs. VTVT, ESLA, ELEV, RAPT, CLNN, LTRN, CASI, TPST, PASG, and ATNM
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include vTv Therapeutics (VTVT), Estrella Immunopharma (ESLA), Elevation Oncology (ELEV), RAPT Therapeutics (RAPT), Clene (CLNN), Lantern Pharma (LTRN), CASI Pharmaceuticals (CASI), Tempest Therapeutics (TPST), Passage Bio (PASG), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "pharmaceutical products" industry.
Eyenovia vs.
vTv Therapeutics (NASDAQ:VTVT) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.
vTv Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
vTv Therapeutics received 178 more outperform votes than Eyenovia when rated by MarketBeat users. However, 64.68% of users gave Eyenovia an outperform vote while only 57.80% of users gave vTv Therapeutics an outperform vote.
vTv Therapeutics has higher revenue and earnings than Eyenovia. vTv Therapeutics is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
vTv Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 150.72%. Eyenovia has a consensus target price of $2.00, indicating a potential upside of 3,289.83%. Given Eyenovia's higher probable upside, analysts clearly believe Eyenovia is more favorable than vTv Therapeutics.
In the previous week, Eyenovia had 3 more articles in the media than vTv Therapeutics. MarketBeat recorded 3 mentions for Eyenovia and 0 mentions for vTv Therapeutics. Eyenovia's average media sentiment score of 0.36 beat vTv Therapeutics' score of -0.55 indicating that Eyenovia is being referred to more favorably in the news media.
17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 25.8% of Eyenovia shares are owned by institutional investors. 1.3% of vTv Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Eyenovia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
vTv Therapeutics has a net margin of 0.00% compared to Eyenovia's net margin of -114,639.41%. vTv Therapeutics' return on equity of -184.64% beat Eyenovia's return on equity.
Summary
Eyenovia beats vTv Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
This page (NASDAQ:EYEN) was last updated on 1/21/2025 by MarketBeat.com Staff
